MedTrace Logo

A Study of Emapalumab for Pediatric Aplastic Anemia

NCT06430788 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.

Funding Source- FDA OOPD

Conditions

  • Aplastic Anemia
  • Cytopenia
  • Hypocellular Marrow

Interventions

BIOLOGICAL

Emapalumab

Emapalumab is an interferon gamma (IFNγ) blocking antibody

Sponsors & Collaborators

Principal Investigators

  • Andromachi Scaradavou, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
0 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2029-05-21
Completion
2029-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06430788 on ClinicalTrials.gov